Lyophilization container and method of using same

Information

  • Patent Grant
  • 11634257
  • Patent Number
    11,634,257
  • Date Filed
    Wednesday, September 2, 2020
    3 years ago
  • Date Issued
    Tuesday, April 25, 2023
    a year ago
Abstract
Provided is a multi-part lyophilization container for lyophilizing a fluid, storing the lyophilizate, reconstituting the lyophilizate, and infusing the reconstituted lyophilizate into a patient, including a method of using same. The container includes a front surface, a back surface, a non-breathable section including a port region, a breathable section including a breathable membrane, and an occlusion zone encompassing a boundary between the non-breathable section and the breathable section. The non-breathable section is configured to accommodate any of a liquid, a solid, a gas or combination thereof. The breathable section is configured to accommodate only a gas. The method includes creating a temporary seal between the non-breathable section of the container and the breathable section, inputting a liquid into the non-breathable section, freezing the liquid, removing the temporary seal to allow vapor transport between the non-breathable section and the breathable section, and adding heat energy the frozen liquid under vacuum.
Description
BACKGROUND

The present application describes a device and related method for lyophilizing (freeze-drying) and storing a fluid. The device is a continually evolving, multi-section lyophilization container that evolves throughout the stages of filling, lyophilization, storage, reconstitution and infusion. The method is a means by which the device is manipulated throughout the lyophilization process. In embodiments of the instant application, lyophilization of the fluid occurs in situ within the multi-section lyophilization container.


Any suitable fluid may be lyophilized and stored using the devices and techniques described in this disclosure, including human and animal blood and related blood products, such as blood plasma.


The advantages of lyophilization and the relative benefits of storing and transporting lyophilized products have been known for many years. Unfortunately, several technical challenges must be addressed before lyophilization can enjoy greater adoption in the blood and blood related fields. One such challenge is that many methods use glass containers which tend to be large and breakable. In this respect, a flexible pouch would be an improvement. Further, current methods suffer from prolonged drying times resulting from restricted vapor transmission to the condenser of the lyophilizer. Another challenge is that current lyophilization techniques include pathways by which both the blood, and the technician, may be subject to contamination. A yet further challenge, specific to techniques utilizing a flexible container including a breathable membrane, is a limitation in vapor flow caused by a wetting and fouling (i.e., blocking) of the breathable membrane throughout the lyophilization process which leads to relatively slow lyophilization times. Additionally, current devices include an arrangement of breathable and non-breathable elements which fails to provide adequate total breathable surface area, resulting in underperformance.


Because of these and other problems associated with the state of the art, the traditional approach to freezing, storing and transporting frozen blood and blood products remains the approach most commonly deployed. Problematically, traditional freezing, storage and transportation of blood and blood products requires the blood to be maintained at a temperature that is typically −20° C. or below to maintain protein integrity. This, in turn, necessitates cold chain management which dramatically increases the costs and logistical hurdles associated with traditional methods. For example, cold chain management requires the implementation of systems and protocols capable of effectively processing orders and providing reliable transportation and delivery of frozen products that then require thawing prior to transfusion. These requirements can present significant challenges in developing regions suffering from lack of resources and lack of infrastructure capable of accommodating the complex requirements of the cold chain logistics just described. Often, the result is that patients in dire need of transfusion in developing regions perish. Accordingly, despite their predominance, traditional methods remain burdened by disadvantages, particularly in connection with blood requiring storage for long periods or requiring temperature-controlled transportation over large distances.


Consequently, a strong interest remains in lyophilization as an alternative to traditional methods for freezing, storing and transporting blood and blood products. A lyophilized blood product, such as plasma, may have much smaller mass than a traditional product, has a longer shelf life and does not require extensive cold chain management or lengthy thawing procedures. Additionally, since a lyophilized blood product can be easily and rapidly reconstituted at its point of use, a lyophilized blood product is often preferable in battlefield environments, in emergency response situations and in various clinical applications. For these and other reasons, there remains a need to improve current lyophilization devices and techniques in relation to blood and blood products.


Although specific embodiments of the present application are provided in view of these and other considerations, the specific problems discussed herein should not be interpreted as limiting the applicability of the embodiments of this disclosure in any way.


SUMMARY

This summary is provided to introduce aspects of some embodiments of the present application in a simplified form and is not intended to comprise an exhaustive list of all critical or essential elements of the claimed invention, nor is it intended to limit the scope of the claims.


Embodiments provide for a multi-part lyophilization container. The container includes a front surface, a back surface, a non-breathable section including a port region, a breathable section including a breathable membrane, and an occlusion zone encompassing a boundary bridging the non-breathable section and the breathable section. The non-breathable section is configured to accommodate any of a liquid, a solid and a gas, whereas the breathable section is configured to accommodate only a gas.


In another aspect, provided is a method of lyophilizing a fluid in a multi-part container. The method includes creating a temporary seal dividing a non-breathable section of the container and a breathable section of the container, inputting a liquid into the non-breathable section of the container, freezing the liquid, opening the temporary seal to allow vapor flow between the non-breathable section of the container and the breathable section of the container, and adding heat energy to the frozen liquid under vacuum, wherein the breathable section is configured to accommodate only a gas.


Further embodiments of the present application include additional methods and devices and systems for lyophilizing fluids. The fluid may be any suitable liquid, including human or animal plasma.





BRIEF DESCRIPTION OF THE DRAWINGS

Non-limiting and non-exhaustive embodiments are described with reference to the following figures.



FIGS. 1A and 1B are plan and perspective views of a lyophilization container according to an embodiment of the present application;



FIGS. 2A and 2B are plan and perspective views of another lyophilization container according to an embodiment of the present application;



FIG. 3A is a plan view of a non-breathable section of a lyophilization container according to an embodiment of the present application;



FIG. 3B is an expanded view of the port region of the non-breathable section of the lyophilization container of FIG. 3A;



FIG. 4 is a plan view of a breathable section of a lyophilization container according to an embodiment of the present application;



FIG. 5 is a section view of the Hold Open Device (HOD) of the breathable section of the lyophilization container of FIG. 4;



FIG. 6 is an expanded view of the HOD capture void of the breathable section of the lyophilization container of FIG. 4;



FIG. 7 is a side section view of an alternative configuration of an occlusion zone according to an embodiment of the present application;



FIG. 8 is a workflow schematic illustrating an intermittent occlusion of a lyophilization container according to an embodiment of the present application; and



FIG. 9 is workflow schematic illustrating an intermittent occlusion of a lyophilization container according to another embodiment of the present application.





DETAILED DESCRIPTION

The principles described in the present application may be further understood by reference to the following detailed description and the embodiments depicted in the accompanying drawings. Although specific features are shown and described below with respect to particular embodiments, the present application is not limited to the specific features or embodiments provided. Moreover, embodiments below may be described with respect to lyophilizing and storing human or animal blood or blood components; however, such descriptions are merely illustrative. Those of skill in the art will appreciate that embodiments of this disclosure may be used in connection with the lyophilization of any suitable liquid.


Embodiments of the present application refer to a closed, sterile container, including sterile fluid pathways, for lyophilizing and storing a fluid, thus obviating the need for a clean room. Moreover, embodiments described in this application may be implemented in conjunction with many conventional, commercially available lyophilizers, such as the EPIC Small Production Lyophilizer by Millrock Technology. Accordingly, the devices and techniques described in this application may be more widely distributed and widely accessible than are existing devices and techniques. Further advantages of the various enumerated embodiments are noted throughout this disclosure.


The terms “multi-part container,” “container,” “lyophilization container,” “multi-part lyophilization container,” and the like, are used interchangeably throughout this disclosure. Similarly, the term “breathable,” with respect to materials and membranes, may be used interchangeably with the term “semi-permeable.” The term “non-breathable” may be used interchangeably with the term “non-permeable.”



FIGS. 1A and 1B are plan and perspective views of a lyophilization container according to an embodiment of the present application.


Referring to FIG. 1A, the lyophilization container 100 includes a non-breathable section 102, including a port region 104; a breathable section 106, including a breathable membrane 108 and an inner membrane weld 110; an outer perimeter weld 112; and an occlusion zone 114.


As shown in FIGS. 1A and 1B, the lyophilization container 100 is essentially rectangular and is comprised of two principal sections: non-breathable section 102 and breathable section 106, joined in occlusion zone 114. Non-breathable section 102 and breathable section 106 are in communication with one another in a native or normal state, and together encapsulate the container cavity. Port region 104 defines an area within non-breathable section 102 that is configured to incorporate one or more fluidic ports. Breathable membrane 108 is incorporated into breathable section 106 by inner membrane weld 110, which is a sterile seal. Outer perimeter weld 112 is also a sterile seal and defines the outer perimeter of the lyophilization container 100, including the port region 104.


The overall length of the lyophilization container 100, denoted as “L,” including both the non-breathable section 102 and the breathable section 106, is approximately 50 cm. In embodiments, L may be any dimension suitable for placement of the container in a shelf lyophilizer or other lyophilizer, any dimension required to increase or decrease vapor flow resistance, or any dimension to increase or decrease the thickness of the frozen liquid, such as between 30 cm and 70 cm, or more preferably between 40 cm and 60 cm. The width of the container, denoted as “W,” is approximately 15 cm. In embodiments, W may any suitable dimension, such as between 10 cm and 20 cm, or more preferably, between 13 cm and 17 cm. In the example shown, the length of non-breathable section 102, measured from the midpoint of the occlusion zone 114, is approximately 28 cm. In embodiments, the length of non-breathable section 102 may be any suitable dimension, such as between 20 cm and 40 cm, or more preferably, between 24 cm and 32 cm. The length of breathable section 106, measured from the midpoint of the occlusion zone 114, is approximately 22 cm. In embodiments, the length of breathable section 106 may be any suitable dimension, such as between 10 cm and 30 cm, or more preferably, between 18 cm and 26 cm. The exemplary dimensions of 15 cm by 50 cm described above are suited to lyophilize approximately 300 ml of liquid plasma. The lyophilization of larger or smaller volumes would suggest different preferred dimensions.


Although FIGS. 1A and 1B depict an essentially rectangular container, some embodiments might include geometries that deviate from the rectangular shape. For example, the width of only occlusion zone 114 might be reduced to less than the width W of the embodiment shown. Such an adjustment may result in an essentially hourglass shaped container as opposed to a container having a rectangular shape. This type of adjustment in occlusion zone 114


dimension may better facilitate temporarily sealing of the occlusion zone during the lyophilization process.


The “top” or “front” of the lyophilization container 100 shown is essentially identical to the “bottom” or “back” of the container 100. That is, each of the top and the bottom of the container includes non-breathable material of the non-breathable section and breathable membrane of the breathable section. In alternative embodiments, the breathable membrane comprises a continuous sheet including an isoclinal (i.e., hairpin) fold causing the breathable membrane to bridge a portion of the top or front surface and a portion of the bottom or back surface. In yet another alternative embodiment, the breathable section might comprise breathable membrane only on the top of the container or only on the bottom of the container. In operation, the lyophilization container 100 is typically placed on a lyophilizer shelf such that the bottom or back of the container faces the lyophilizer shelf That is, during lyophilization, a portion of each of the non-breathable section 102 and the breathable section 106, including breathable membrane, face the lyophilizer shelf. Non-breathable section 102 should be in sufficient direct or indirect thermal communication with the lyophilizer shelf to facilitate conductive and/or radiative heat transfer. In yet further embodiments, only the non-breathable section might be in contact with the shelf and the breathable section might reside off the shelf. In certain other embodiments, the lyophilization container may be disposed vertically within a lyophilization chamber.


In operation, lyophilization container 100 exchanges fluids via ports positioned in the port region 104 of non-breathable section 102. Fluid exchanges occur only during initial filling of the container with liquid plasma and during the post-lyophilization filling of the container with sterile water for reconstitution and transfusion into a patient. Both prior to, and after, the sublimation of the frozen fluid and removal of vapor during lyophilization, non-breathable section 102 and breathable section 106 are isolated from one another by a creation of an occlusion of the container in the occlusion zone 114 encompassing the transition between the non-breathable section 102 and breathable section 106. In this respect, the position of the occlusion within the occlusion zone 114 defines the boundary between non-breathable section 102 and breathable section 106.


Outer perimeter weld 112 defines the outer perimeter of the container and includes port region 104 of the non-breathable section 102. Outer perimeter weld 112 has an average width of approximately 7 mm. In embodiments; however, outer perimeter weld 112 may be any suitable width, such as between 2 mm and 12 mm, and may further be variable by up 3 mm along its length.


Inner membrane weld 110 surrounds the breathable membrane 108 within breathable section 106. Inner membrane weld 110 also has average width of approximately 7 mm; however, in embodiments, inner membrane weld 110 may be any suitable width, such as between 2 mm and 12 mm, variable by up 3 mm along its length.


Port region 104 is the portion of the outer perimeter weld 112 of non-breathable section 102 configured to incorporate one or more fluidic ports capable of forming a sterile fluid pathway between the lyophilization container and any of several other fluid containers. Port region 104 is also configured to facilitate transfusion to a patient.


In addition to encompassing the boundary between non-breathable section 102 and breathable section 106, occlusion zone 114 is adapted to facilitate the evolution of the container throughout its life cycle. Occlusion of the container 100 in the occlusion zone 114 creates a temporary impermeable or substantially impermeable seal, eliminating the fluid communication between the non-breathable section 102 and breathable section 106. In operation, an initial occlusion isolates non-breathable section 102 from the breathable section 106 prior to the introduction of fluid via ports in port region 104. Removal or opening of the occlusion upon formation of a frozen ice structure (i.e., a frozen fluid structure to be lyophilized) allows the container to resume its native state, thus restoring the original container cavity. In the restored state, the container again provides a generous, open pathway for vapor flow between the non-breathable section 102 and breathable section 106. The ability of the container to continually evolve in form and function ensures that no contact occurs between the subject fluid and the breathable section 106 by causing the subject liquid to be isolated and frozen in only the non-breathable section 102 and allowing only the vapor flow from sublimation and desorption to contact the breathable section 106. That is, embodiments of the present application are configured to create a continuous physical separation between the subject liquid and the breathable section 106. Accordingly, the non-breathable section 102 is adapted to accommodate any of a solid, a liquid or a gas, whereas the breathable section 106 is adapted to accommodate only a gas (i.e., a gas only section).


Occlusion zone 114 is approximately 3 cm in width; however, in embodiments, the occlusion zone may be between 1 cm and 5 cm wide, such as between 2 cm and 4 cm wide. The nearest edge of the occlusion zone is preferably positioned within 5 cm of the breathable membrane 108 of the breathable section 106, but may be positioned between 0.2 cm and 10 cm, such as between 3 cm and 7 cm, from the breathable membrane 108. The occlusion zone 114 should be sufficiently proximate to the breathable membrane 108 to ensure the efficient use of container materials and to minimize the distance that vapor must flow to exit the container, yet sufficiently distant from the breathable membrane 108 to allow for the creation of a permanent seam in non-breathable material between the occlusion and the breathable membrane post lyophilization. The creation of a permanent seam in non-breathable material between the occlusion and the breathable membrane material post-lyophilization creates a permanent seal, allowing for a permanent separation of container sections and the removal and disposal of the breathable section 106. Removal of the breathable section 106 is the final step in the evolution of the container. Removal of the breathable section 106 minimizes the volume and the mass of the final product, which is desirable for both transportation and storage. Additionally, removal of breathable section 106 transforms non-breathable section 102 into a more traditional container suitable for fluid transfusion into a patient.


In embodiments, a visual indication may demarcate the occlusion zone 114. For example, the occlusion zone 114 may be indicated by lines, by a color scheme, or by any other conventional means of visual indication. In embodiments, a choice of material or texture may indicate the position of the occlusion zone 114. For example, a textured surface may provide a visual position indication designed to indicate the position and boundaries of the occlusion zone 114. In exemplary embodiments, particular materials or textures may also be chosen for one, or both, of the inner or outer surfaces of container material in the occlusion zone 114 to provide improved sealing characteristics (e.g., smooth materials), to impart an improved ability of the materials to pull apart from one another, or to pull apart from ice formed during freezing of the subject fluid (e.g., textured materials). Notably, materials chosen for the occlusion zone 114 may be textured or smooth and may be like or dissimilar to one another. Material and design choices for the occlusion zone 114 should consider that an intermittent application and removal of an occlusion in the occlusion zone 114 must reliably result in the intermittent creation and removal of a temporary impermeable seal. However, it should be noted that in some circumstances, an occlusion may not be a perfectly impervious or hermetic barrier or seal. That is, in certain situations, minor or insubstantial leakage across an occlusion may be acceptable.


The creation of an occlusion of the container in the occlusion zone 114 may occur by any known means, such as by manual clamping, or by various automated or semi-automated means. Exemplary manual clamps may include, but are not limited to, screw clamps or bag clips that are in common usage. Various automated or semi-automated occlusion means may, for example, include mechanical compression means incorporated into the shelves of, or the shelf system of, a lyophilizer. In all cases, the means chosen for creating an occlusion must ensure that fluids input into the non-breathable section 102 via port region 104 do not contact breathable membrane 108 of breathable section 106 at any point.


In embodiments described throughout this disclosure, various additional features may also be included in non-breathable section 102. For instance, a section of relatively clear container material may be incorporated into non-breathable section 102 to allow visual inspection of the subject fluid before, during or after lyophilization.


In the embodiment shown in FIG. 1, the non-breathable material is ethylene-vinyl acetate (EVA). EVA exhibits several advantageous properties including its relative strength, its relative elasticity and resilience at low temperatures, its relative crack resistance and the ease with which it may be manufactured. EVA also exhibits comparatively favorable thermal transfer properties. Nonetheless, in embodiments, material choices for non-breathable material are not limited, and may include a variety of non-breathable materials that exhibit preferable characteristics, such as thermoplastic elastomers (TPEs). TPEs are relatively soft and flexible, and exhibit advantages for several healthcare applications. For instance, TPEs can be sterilized using autoclaves, gamma irradiation, or ethylene oxide. Further, TPEs can be designed to be biocompatible, to have high purity, and to have low levels of extractable and leachable substances. TPEs are also recyclable and are a comparatively favorable material for cryogenic storage.


Linear, low density polyethylene (LLDPE) may also be desirable for use as non-breathable material. LLDPE is preferable to certain other materials due to its favorable puncture and impact resistance and to its high tensile strength. For instance, as compared to LDPE, LLDPE exhibits superior flexibility and resistance to cracking, thus making it more suitable for certain thin film applications.


Materials selected for non-breathable material must maintain strength at low temperatures (e.g., −40° C. to −60° C.) as is required for lyophilization. Certain materials exhibiting a low surface energy and super-hydrophobicity may further be incorporated into the interior surface of the non-breathable section to facilitate an improved release of the ice structure from the inner surfaces of the container after freezing and before drying.


In embodiments, various additional or alternative plastic films may be incorporated into non-breathable section 102, or to all areas of the container with non-breathable material for a particular purpose or application. For example, materials may be implemented for any of improved impermeability, improved heat sealing characteristics or improved mechanical strength.



FIGS. 2A and 2B are plan and perspective views of another lyophilization container according to an embodiment of the present application.


Referring to FIGS. 2A and 2B, the lyophilization container 200 includes a non-breathable section 202, including a port region 204; a breathable section 206, including a Hold Open Device (HOD) 208, a breathable membrane 210; an inner membrane weld 212; an outer perimeter weld 214; and an occlusion zone 216.


As shown in FIGS. 2A and 2B, the lyophilization container 200 is essentially the same as the lyophilization container of FIGS. 1A and 1B, further including a Hold Open Device (HOD) 208. In the embodiment shown, HOD 208 is a semi-rigid, flat-sided elliptical fixture, captured within the lyophilization container 200. HOD 208 is in an open mode in its native state, disposed circumferentially within the container cavity to facilitate a pathway for vapor flow between non-breathable section 202 and breathable section 206. HOD 208 is positioned entirely within the breathable section 206, bridging portions of breathable membrane 210 and non-breathable material. Notably, in embodiments, HOD 208 shape is not limited, and various alternative HOD 208 designs may be implemented, such as a modified rectangle or other shape capable of facilitating vapor flow between container sections.


In various embodiments, HOD 208 may be a rigid or a semi-rigid fixture captured within, or fastened to the outside of, the breathable section of the lyophilization container 200. The exact position of the HOD 208 may vary. For example, the HOD 208 may be positioned entirely within the non-breathable section, or within a region of non-breathable material of the breathable section. Alternatively, HOD 208 may extend into portions of both non-breathable material and breathable material. In yet further embodiments, HOD 208 may be positioned and configured to assist in the creation of the temporary seal between bag sections. Preferably, HOD 208 is positioned proximate to the occlusion zone to minimize the distance between the HOD 208 and the placement of an occlusion in the occlusion zone 216. In the example shown, the nearest edge of HOD 208 is positioned approximately 2.5 cm from nearest edge of the occlusion zone 216. Nonetheless, HOD 208 placement may be further optimized according to a particular container 200 or occlusion zone 216 configuration.



FIG. 3A is a plan view of a non-breathable section of a lyophilization container according to an embodiment of the present application.


Referring to FIG. 3A, non-breathable section 300 comprises a non-breathable material 302; and an outer perimeter weld 304, including a port region 306 incorporating fluidic ports 308; and a portion of an occlusion zone 310.


Non-breathable section 300 is comprised of the non-breathable material described above. The boundaries of non-breathable section 300 include outer perimeter weld 304, including port region 306, and the midpoint (i.e., estimated position of occlusion) of the occlusion zone. That is, when the container is occluded in the occlusion zone 310, non-breathable section 300 may be defined as the section of the container on the side of the occlusion that is non-breathable. When an occlusion is not present in the occlusion zone 310, the boundary of the non-breathable section may be approximated as the midpoint of the occlusion zone, as shown ion FIG. 3A.



FIG. 3B is an expanded view of the port region of the non-breathable section of the lyophilization container of FIG. 3A.


Referring to FIG. 3B, port region 306 includes three ports 308. The ports 308 define the manner in which the lyophilization container exchanges fluids with other vessels and containers. The ports 308 must accordingly provide secure, sterile connections which eliminate the potential for breakage, contamination or misconnection, and must function across every phase of use including filling, lyophilization, storage, reconstitution and, in the case of lyophilized plasma, infusion. In embodiments, the configuration and number of ports 308 may vary depending on a particular application. For instance, embodiments may include between 1-5 ports, such as 3 ports. Ports 308 may further include connections which are either resealable or non-resealable.


Ports 308 shown in FIG. 3B may be adapted to include a variety of ports. For example, ports 308 may include any of a spike port, a docking port and a reconstitution port. A spike port may be included to facilitate reinfusion of a reconstituted blood product into a patient. An exemplary spike port may be any weldable spike port known in the art which is compatible for use in lyophilization containers. Examples of suitable materials for use in spike port include polyvinyl chloride (PVC) and ethylene-vinyl acetate (EVA) (e.g., such as is manufactured by Carmo of Denmark). In other embodiments, a polypropylene (PP) spike port may be desirable.


A docking port may be included to connect the lyophilization container with another fluid container, such as a blood pooling container or pooling container set. A docking port may further be used to introduce air or other gas into the lyophilization container. Air or other gas may, for example, be introduced to create a vapor space above the subject liquid or to regulate pH. An exemplary docking port comprises PVC tubing. In embodiments, however, dock port may include any suitable docking fixtures or tubing which are known in the art.


A reconstitution port may be included to accept an inflow of reconstitution fluid into the lyophilization container. An exemplary reconstitution port 308 may include a male or a female Luer-Lock type connection in order to prevent accidental misconnection. One example of such a connection is the Correct Connect® system that is a standardized connection system used in apheresis applications. In embodiments, various one-way valves and other means for providing an error proof connection may also be adapted for use with the reconstitution port 308. Notably, the type of connection used for reconstitution is particularly important. That is, the handling of reconstitution fluids entails the potential risk of a direct transfusion of the reconstitution fluid into the patient. Such an event constitutes a serious and immediate health hazard. For this reason, it is important that the reconstitution port and related connections be highly conspicuous and be incompatible with the other ports in order to avoid an occurrence of accidental misconnection.



FIG. 4 is a plan view of a breathable section of a lyophilization container according to an embodiment of the present application.


Referring to FIG. 4, breathable section 400 comprises an outer perimeter weld 402, including a Hold Open Device (HOD) capture void 404; a HOD 406; a breathable membrane 408; an inner membrane weld 410; and a portion of an occlusion zone 412.


The boundaries of breathable section 400 include outer perimeter weld 402 and the midpoint (i.e., estimated position of occlusion) of the occlusion zone 412. That is, when the container is occluded in the occlusion zone 412, breathable section 400 may be defined as the section of the container on the side of the occlusion that is breathable. When an occlusion is not present in the occlusion zone 412, the boundary of the breathable section 400 may be approximated as the midpoint of the occlusion zone, as shown in FIG. 4.


Breathable section 400 comprises breathable membrane 408 embedded within non-breathable material. Inner membrane weld 410 is a sterile seal defining the boundary between the breathable membrane and non-breathable material. Outer perimeter weld 402 is a sterile seal defining the outer perimeter of breathable section 400. Outer perimeter weld 402 includes HOD capture voids 404 for capturing HOD 406 within the container.


In certain embodiments, breathable membrane 408 may comprise only one material. In other embodiments, breathable membrane 408 may comprise two or more materials, for example, breathable membrane may comprise a membrane laminate consisting of a breathable membrane and a backing material. In embodiments comprising a laminate, membrane material may include an expanded polytetrafluoroethylene (PTFE). PTFE membranes are preferable to other membranes for several reasons. For instance, expanded PTFE provides a microstructure that may be precisely controlled, which results in the ability to obtain a desired a pore size distribution. Further, expanded PTFE is essentially inert, is operable across a large temperature range and can withstand harsh environments. For at least these reasons, expanded PTFE provides characteristics which are preferable in comparison to other materials.


An ideal pore size for an expanded PTFE membrane may be between 0.1 micron (μm) to 0.5 μm, such as 0.15 μm to 0.45 μm, or 0.2 μm to 0.3 μm. A PTFE membrane having pore sizes in this range exhibits relatively efficient vapor transmission characteristics while maintaining a sterile barrier capable of eliminating the ingress of contaminants.


A reinforcing material is designed to bond the breathable section 400 to the non-breathable section without impairing the functionality of the breathable membrane 406. The addition of a reinforcing material improves the structural integrity of the container. That is, the reinforcing material must bond with the breathable membrane, must bond with the non-breathable material, and must have a pore size that does not impede vapor transmission across the breathable membrane during lyophilization. Exemplary reinforcing materials are preferably a 50:50 polypropylene/polyethylene blend. In embodiments, however, preferable blend ratios may vary and may be between 40:60 and 60:40 polypropylene:polyethylene. Polypropylene backing materials are advantageous, inter alia, for their transition glass temperatures which are low enough to avoid material degradation during freezing at lyophilization temperatures, such as −40° C.


In embodiments comprising a laminate, various additional or alternative plastic films may be incorporated into the breathable membrane or to the backing material to impart desired characteristics, such as favorable heat sealing characteristics, improved permeability, or for overall mechanical strength.



FIG. 5 is a section view of the Hold Open Device (HOD) of the embodiment shown in FIG. 4.


Referring to FIG. 5, HOD 500 is a semi-rigid fixture having an essentially ovular or elliptic shape incorporating pointed ends and flat sides. In the embodiment shown, HOD 500 is captured within the breathable section proximate to the occlusion zone. In other embodiments, the HOD 500 may be coupled to the outside of the container. Although generally the HOD 500 is designed to reside in, or on the outside of, the breathable section of the container, physically separated from the subject liquid throughout the container life cycle, various further embodiments could include HOD 500 in the non-breathable section.


Incorporation of the elliptic HOD 500 creates a generous open region above a thin, uniform structure of ice. Preferably, the thin, uniform ice structure has a thickness of from 6 mm to 13 mm, such as 10 mm, to maximize the efficacy and efficiency of the container. Incorporating the HOD 500 assists in securing a generous vapor pathway between the non-breathable section and the breathable section and reduces overall vapor pressure in the container during sublimation. HOD 500 may also compliment the intermittent creation of occlusions (i.e., temporary impermeable or substantially impermeable seals) in the occlusion zone. For example, HOD 500 may impart a tautness to container material which improves the reliability or quality of an occlusion. HOD 500 may likewise assist in the pulling apart of occlusion zone surfaces throughout the removal of the occlusion, thereby facilitating a re-creation of the vapor pathway between container sections. The pulling apart of occlusion zone surfaces can be complicated by the existence of ice formed on, or directly adjacent to, the occlusion as a result of an inadvertent wetting of occlusion zone materials by the subject fluid prior to the freezing step. Such wetting may be caused during the filling step, or by movement of the container. In this respect, HOD may compliment other means employed to address problems associated with the pulling apart of occlusion zone surfaces described herein, including material and related texture choices.


In the embodiment shown, HOD 500 comprises a semi-rigid silicone. In embodiments, however, several other rigid or semi-rigid materials may be implemented. For example, PVC or certain other synthetic plastic polymers may be preferable HOD 500 material. In certain embodiments, semi-rigid materials may be incorporated for their ability to flex in response to an occlusion of the occlusion zone. In such embodiments, HOD may compress to some degree upon occlusion of the occlusion zone, and may rebound toward an original shape upon removal of the occlusion. Such shape-memory behavior may assist in the maintaining of an open region above the subject liquid or ice and in the creation of generous vapor pathway between container sections. This may be especially pronounced in embodiments combining a semi-rigid HOD with other flexible container materials.


The external height of HOD 500 shown in FIG. 5 is 2.8 cm; however, in embodiments, external height may vary from 1.5 cm to 4 cm. The internal height is approximately 2.2 mm; however, in embodiments, the internal height may vary between 1 cm to 3 cm depending on the exact configuration and size of HOD. HOD width is the approximate width of the lyophilization container. HOD 500 depth is approximately 3.5 cm; however, in embodiments HOD depth may be between 0.5 cm and 4 cm. The overall size and shape of HOD 500 is not limited, and accordingly may vary depending on the desired configuration of a particular embodiment.



FIG. 6 is an expanded view of the Hold Open Device (HOD) capture void of the breathable section of the lyophilization container of FIG. 4.


Referring to FIG. 6, HOD capture void 600 includes a void space 602, sidewalls 604 and outer perimeter weld 606.


HOD capture void 600 is essentially an indentation or a void within outer perimeter weld 606 in which the HOD is securely captured. As shown, the void space 602 has a width which is slightly larger than the width of the HOD to accommodate the HOD. Sidewalls 604 are angled at approximately 45 degrees to the longitudinal axis of the outer perimeter weld. Void space 602 depth is approximately 4 mm.


In embodiments, each of the parameters of the HOD capture void 600 can be optimized. For instance, HOD void space 602 width may vary according to a particular container configuration and may be as much as 20 percent greater than the width of the HOD. Likewise, HOD void space 602 depth may vary. For example, HOD void space 602 depth may be between 1 mm and 6 mm, such as between 2 mm and 4 mm.


In embodiments, the design of HOD capture void 600 may also vary. For instance, sidewall 604 angle may be lesser or greater than 45 degrees. In some cases, the sidewalls 604 may be perpendicular to the longitudinal axis of the outer perimeter weld 606. In further embodiments, sidewall 604 angles may be dissimilar. Likewise, HOD void space 602 depth may vary along its length. That is, in embodiments, HOD capture void 600 may be asymmetrical or irregular.



FIG. 7 is a side section view of an alternative configuration of an occlusion zone according to an embodiment of the present application.


Referring to FIG. 7, occlusion zone 700 includes top material 702; dam 704; and a liquid 706.


In the embodiment shown in FIG. 7, occlusion zone 700 is incorporated into a lyophilization container disposed horizontally on a lyophilizer shelf. Top material 702 of occlusion zone 700 comprises non-breathable material and is positioned opposite the container cavity from dam 704. Dam 704 is a rigid or semi-rigid container feature capable of maintaining a segregation of the liquid 706 input to the non-breathable section. Dam 704 height measured from the shelf of the lyophilizer can be any height which exceeds the height of liquid input into non-breathable section. In this respect, dam 704 prohibits the flow of fluid from non-breathable section into breathable section, as shown in FIG. 7.


Dam 704 shown in FIG. 7 comprises a dome shape; however, in embodiments, other dam designs may be desirable. For instance, dam designs including a flat top, or dam designs configured to cooperate with a particular occlusion device or member (not shown) may be desirable. Similarly, textured materials may be included in dam designs to assist in the creation of a temporary impermeable seal during occlusion. In yet further embodiments, dam features may be incorporated into a lyophilization container designed to hang vertically. In embodiments, a dam may be included on one or both sides of an occlusion zone to maintain a segregation of the fluid input into the non-breathable section.


As noted, embodiments of the lyophilization container(s) described herein are configured to continually evolve as the lyophilization process moves through its cycle. Exemplary workflows included below describe the manner in which container embodiments may be manipulated to accomplish container evolution.



FIG. 8 is a workflow schematic illustrating an intermittent occlusion of a lyophilization container according to an embodiment of the present application.


Referring to FIG. 8, in step 802, an occlusion is created in the occlusion zone. In step 804, a subject fluid (e.g., blood plasma) is introduced into the non-breathable section through a port in the port region (e.g., a docking port). In step 806, the liquid in the container is frozen, creating a thin, uniformly thick structure of ice in the non-breathable section. In step 808, the occlusion is removed (i.e., the temporary seal is opened) from the occlusion zone. In step 810, vacuum and heat energy are applied to accomplish sublimation and desorption, causing a phase change in the ice structure from the solid phase directly to the vapor phase. Vapor released from the ice structure flows through the container cavity via the unoccluded occlusion zone and escapes through the breathable section, leaving the lyophilized plasma cake (i.e., the ice structure now dehydrated as a result of lyophilization) in the non-breathable section. In step 812, the container is again occluded in the occlusion zone to prevent contamination of the lyophilizate with moisture and oxygen from air. In step 814, a permanent seam is created in non-breathable material of the breathable section between the occlusion and the HOD. In step 816, the container is divided at the permanent seam and the breathable section is discarded, leaving the lyophilizate in the non-breathable section which has now evolved into its final form as a medical infusion bag.


In step 804, the introduction of fluid may be referred to as pre-loading. During preloading, between 250 ml to 500 ml of fluid (e.g., blood plasma) are input into the non-breathable section of the multi-part lyophilization container. The container is then placed horizontally on the shelf of a lyophilizer, “front” or “top” side upward facing.


In step 810, sublimation and desorption include the application of heat energy and vacuum. Preferable drying temperatures may range from −20° C. to −40° C., such as −25° C. Owing to the generous vapor pathway between container sections and the large surface area of breathable membrane in the breathable section, vapor from the ice structure escapes relatively freely from the container. This, in turn, results colder temperatures during lyophilization and therefore improved quality of the final dry product. In addition, a diminution in sublimation times as compared to conventional lyophilization techniques is realized. Further, embodiments result in reduced vapor pressures in, and an increase in mass transfer across, the breathable section, which may result in a sufficient drying of the ice structure solely during a single drying phase. That is, embodiments may obviate the need for the secondary drying phase of traditional 2-phase drying methods (i.e., desorption).


In step 812, an occlusion is made in the occlusion zone of the container, creating a temporary seal between the breathable section and the non-breathable section.


In step 814, a permanent seam is created, isolating the lyophilized cake in the non-breathable section. In the schematic shown, permanent seam step 814 is a discreet step. That is, an ancillary piece of equipment is used to create the permanent seam or seal. In further examples, permanent seam step 814 may be integrated into occlusion step 812. In such embodiments, the occlusion means (e.g., a clamp) may incorporate the permanent sealing means.


In step 816, the complete removal of the breathable section represents the final evolution of the container. Removal of the breathable section eliminates the potential for moisture and oxygen ingress into the dried product, thereby increasing shelf life and plasma stability. Additionally, the reduced size of the final lyophilizate container is more convenient for each of transportation, storage, reconstitution and infusion.


In further exemplary workflows, steps may be added to the workflow described in FIG. 8. For example, additional steps may include the introduction of gas into the lyophilization container to regulate pH or to create a vapor space above the subject fluid or ice structure. In a further example, an additional step may include backfilling the lyophilization container with an inert gas to regulate container pressure.



FIG. 9 is workflow schematic illustrating an intermittent occlusion of a lyophilization container according to another embodiment of the present application.


Referring to FIG. 9, in step 902, an occlusion is created in the occlusion zone. In step 904, a subject fluid (e.g., blood plasma) is introduced into the non-breathable section through a port in the port region (e.g., a docking port). In step 906, air, inert gas, or a pH regulating gas (e.g., CO2) is introduced into the non-breathable section through a port in the port region (e.g., a docking port). In step 908, the liquid in the container is frozen, creating a thin, uniformly thick structure of ice in the non-breathable section. In step 910, the occlusion is removed from the occlusion zone. In step 912, vacuum and heat energy are applied to accomplish sublimation and desorption, causing a phase change in the ice structure from the solid phase directly to the vapor phase. Vapor released from the ice structure flows through the container cavity via the unoccluded occlusion zone and escapes through the breathable section, leaving the lyophilized plasma cake in the non-breathable section. In step 914, the container is backfilled with an inert gas to raise container pressure to partial atmospheric pressure. In step 916, the container is occluded in the occlusion zone to prevent contamination of the lyophilizate. In step 918, a permanent seam is created in the non-breathable material of the breathable section between the occlusion and the HOD. In step 920, the container is divided at the permanent seam and the breathable section is discarded, leaving the lyophilized end-product in the non-breathable section.



FIG. 9 essentially represents a departure from the workflow of FIG. 8 only in the addition of steps 906 and 914. In step 906, air (or nitrogen or another inert dry gas), or a pH regulating gas (e.g., CO2) is introduced into the lyophilization container. Air can be introduced to create a generous physical separation, i.e., a vapor space, between the container material and the preloaded fluid. In exemplary embodiments, the introduction of a vapor space may cause container pressure to reach between 0.3 Pound per square inch (Psi) and 1.0 Psi, such as 0.5 Psi (approximately 26 mmHG). Advantageously, the creation of a vapor space in the container reduces the amount of ice “sticking” to the container material during and after the freezing step. A pH-regulating gas may be introduced to the lyophilization container to regulate pH. In an alternate embodiment, a pH-regulating gas might be introduced during step 914 described below.


In step 914, the lyophilization container is backfilled to partial atmospheric pressure with pH regulating gas (e.g., CO2). In exemplary embodiments, backfill pressure is 65 Torr (or 65 mmHG) absolute pressure. In embodiments, backfill pressure may range from between 40 mmHG and 90 mmHG, such as between 60 mmHG and 70 mmHG. Once at partial atmospheric pressure, the container is occluded, and then permanently sealed in steps 916 and 918, respectively. Occlusion and/or sealing of the container while at a pressure lower than atmospheric pressure causes the container to collapse and reduce its volume when the container is exposed to atmospheric pressure. This process also secures the pH regulating gas in the non-breathable portion and prevents an ingress of oxygen and moisture into the container. Since the resultant container has been occluded and/or sealed at a pressure that is less than atmospheric pressure, and since final container volume will be in a reduced volume condition once the vacuum of the lyophilizer is removed, the final lyophilized product can be stored and transported more easily. Backfilling in this manner is particularly applicable to container embodiments having flexible materials or components since such a diminution of container volume would not be possible with a rigid, inflexible lyophilization container.


In the workflows described above, the means for creating the occlusion are not limited. For example, occlusion means may be integrated into the flexible container, or may be a reusable piece of equipment external to the container. In all embodiments, occlusion means must be capable of creating a temporary impermeable or substantially impermeable seal between the non-breathable section and the breathable section of the evolving multi-part lyophilization container.


The use of a physical barrier (e.g., a clamp) to segregate fluid in the non-breathable section from the breathable section according to workflows described above eliminates the potential for fluid contact with, and fouling of, the pores of breathable material in the breathable section. Fouling can disrupt the sublimation and desorption aspects of lyophilization, thereby increasing total lyophilization time and reducing the ability to obtain a viable lyophilizate. Accordingly, eliminating the potential for fouling leads to a relative increase in vapor flow which, in turn, results in faster freeze drying, a colder ice temperature during primary drying due to an increased sublimative cooling effect and increased retention of proteins and clotting factors.


Moreover, because the lyophilization container is a closed, sterile system including sterile fluid pathways, embodiments enable lyophilization to occur in both non-sterile environments and in remote locations. In this respect, for example, embodiments allow lyophilization to be performed on-site at an ordinary blood center as opposed to a traditional clean room facility. Container embodiments also allow flexibility for an operator to freeze and maintain a frozen inventory of plasma in a standard freezer, such as that found in typical blood bank settings. At a later time, this previously frozen plasma can be moved to the more specialized lyophilization instrument for sublimation and desorption. Such work flow flexibility results in improved blood logistics and work flow within the blood bank.


A further advantage of embodiments described herein is the ability to remove the non-breathable section of the lyophilization container post-lyophilization. Isolation and removal of the breathable section post-lyophilization results in the creation of a smaller, lighter aseptic container enclosing the final lyophilizate. The resultant container is also both flexible and highly portable. Moreover, since the breathable section is most vulnerable to moisture and oxygen ingress, its removal can be said to improve the shelf stability of the lyophilizate. The novel use of a temporary occlusion described herein makes this advantage possible. That is, in conventional systems utilizing glass containers, a stopper is mechanically applied to a glass lyophilization container prior to the opening of the lyophilizer in order to prevent an ingress of moisture and oxygen into the container. In contrast, present embodiments utilize the temporary occlusion to prevent an ingress of moisture and oxygen into the non-breathable portion of the container until a permanent seal can be made between non-breathable material portions of the front and back of the container.


The ability of embodiments herein to evolve container configuration, yet to remain a closed, sterile system throughout each phase of container lifecycle is highly unique and advantageous in the lyophilization space. That is, the present embodiments evolve to achieve significant advantages over conventional devices and methods during each of filling, lyophilization, transportation, storage, reconstitution and infusion. Accordingly, many of the attributes and advantages described herein are not possible using conventional devices and approaches, which do not evolve and which require a clean room environment. Importantly in this regard, the evolving, multi-part containers described herein should be further considered evolving, multi-function containers insofar as the type and arrangement of container elements allow the container to accomplish various functions throughout its lifecycle.


Notwithstanding the various specific embodiments enumerated in this disclosure, those skilled in the art will appreciate that a variety of modifications and optimizations could be implemented for particular applications. Additionally, the present application is not limited to the lyophilization of blood or blood products. That is, the principles of the present application may be applicable to the lyophilization of many fluids. Accordingly, various modifications and changes may be made in the arrangement, operation, and details of the methods and systems of the present application which will be apparent to those skilled in the art.

Claims
  • 1. A multi-part lyophilization container, comprising: a front surface;a back surface;a non-breathable section;a breathable section including a breathable membrane; andan occlusion zone forming a boundary bridging the non-breathable section and the breathable section, wherein the non-breathable section and the breathable section are disposed on opposite sides of the occlusion zone, and wherein a position of the occlusion zone is indicated by a smooth region of the occlusion zone including a surface texture that is smooth relative to a texture of an adjacent material.
  • 2. The multi-part lyophilization container of claim 1, wherein the smooth region comprises front surface material and back surface material which are a same material.
  • 3. The multi-part lyophilization container of claim 1, wherein the smooth region comprises material which is dissimilar to material of the non-breathable section and the breathable section.
  • 4. The multi-part lyophilization container of claim 1, wherein the smooth region comprises material having an appearance which is dissimilar to an appearance of material of the non-breathable section and of the breathable section.
  • 5. The multi-part lyophilization container of claim 4, wherein the dissimilar appearance is a dissimilar color.
  • 6. A multi-part lyophilization container, comprising: a front surface;a back surface;a non-breathable section;a breathable section including a breathable membrane; andan occlusion zone forming a boundary bridging the non-breathable section and the breathable section, wherein the non-breathable section and the breathable section are disposed on opposite sides of the occlusion zone, and wherein a position of the occlusion zone is indicated by a textured region of the occlusion zone including a surface texture that is rough relative to a texture of an adjacent material.
  • 7. The multi-part lyophilization container of claim 6, wherein the textured region comprises front surface material and back surface material which are a same material.
  • 8. The multi-part lyophilization container of claim 6, wherein the textured region comprises material which is dissimilar to material of the non-breathable section and the breathable section.
  • 9. The multi-part lyophilization container of claim 6, wherein the textured region comprises material having an appearance which is dissimilar to an appearance of a material the non-breathable section and of the breathable section.
  • 10. The multi-part lyophilization container of claim 9, wherein the dissimilar appearance is a dissimilar color.
  • 11. The multi-part lyophilization container of claim 9, wherein the dissimilar appearance comprises lines that demarcate the occlusion zone.
  • 12. The multi-part lyophilization container of claim 6, wherein the smooth region indicates boundaries of the occlusion zone.
  • 13. The multi-part lyophilization container of claim 6, wherein the non-breathable section comprises a section of clear material.
  • 14. The multi-part lyophilization container of claim 1, wherein the smooth region indicates boundaries of the occlusion zone.
  • 15. The multi-part lyophilization container of claim 1, wherein the non-breathable section comprises a section of clear material.
  • 16. The multi-part lyophilization container of claim 4, wherein the dissimilar appearance comprises lines that demarcate the occlusion zone.
  • 17. A multi-part lyophilization container, comprising: a front surface extending a length from a first end of the multi-part lyophilization container to a second end of the multi-part lyophilization container;a back surface extending the length;a non-breathable section disposed adjacent the first end of the multi-part lyophilization container;a breathable section disposed adjacent the second end of the multi-part lyophilization container, the breathable section comprising a breathable membrane; andan occlusion zone disposed along the length between the first end of the multi-part lyophilization container and the second end of the multi-part lyophilization container, the occlusion zone forming a portion of the multi-part lyophilization container bridging the non- breathable section and the breathable section, wherein a position of the occlusion zone along the length is indicated by a region of the occlusion zone including a surface texture that is different from a texture of an adjacent material.
  • 18. The multi-part lyophilization container of claim 17, wherein the surface texture is rough relative to the texture of the adjacent material.
  • 19. The multi-part lyophilization container of claim 17, wherein the surface texture is smooth relative to the texture of the adjacent material.
  • 20. The multi-part lyophilization container of claim 17, wherein region indicates boundaries of the occlusion zone.
Parent Case Info

This patent application is a continuation application of, and claims priority to, U.S. patent application Ser. No. 16/154,976, entitled “Lyophilization Container and Method of Using Same,” filed in the U.S. Patent and Trademark Office on Oct. 9, 2018. U.S. patent application Ser. No. 16/154,976 claims priority to each of U.S. Provisional Patent Application No. 62/569,858, entitled “Lyophilization and Storage Container for Freeze Dried Blood Products,” filed in the U.S. Patent and Trademark Office on Oct. 9, 2017 and U.S. Provisional Patent Application No. 62/571,087, entitled “Lyophilization and Storage Container for Freeze Dried Blood Products,” filed in the U.S. Patent and Trademark Office on Oct. 11, 2017. U.S. patent application Ser. No. 16/154,976 and each of the above-identified provisional patent applications are hereby incorporated by reference in their entirety as if set forth herein in full.

Government Interests

The invention was made with government support under contract number H92222-16-C-0081 awarded by the United States Department of Defense. The government has certain rights in the invention.

US Referenced Citations (400)
Number Name Date Kind
136036 Craven Feb 1873 A
1441570 Fitzgerald Jan 1923 A
1504225 Fitzgerald Aug 1924 A
1956784 Allen May 1934 A
2659986 Hink, Jr. Nov 1953 A
2704075 Cherkin Mar 1955 A
2767117 Crawley Oct 1956 A
2893843 Adam, Jr. Jul 1959 A
2912359 Anigstein et al. Nov 1959 A
3008879 Harvill Nov 1961 A
3024167 Damasukus Mar 1962 A
3057781 Mace et al. Oct 1962 A
3123443 Smeby Mar 1964 A
3187750 Tenczar, Jr. Jun 1965 A
3223593 Aldrich et al. Dec 1965 A
3228841 Cohen et al. Jan 1966 A
3229813 Crowe, Jr. Jan 1966 A
3236732 Arquilla Feb 1966 A
3247957 Kemble Apr 1966 A
3260648 Fox Jul 1966 A
3294523 Morningstar Dec 1966 A
3322634 Fulthorpe May 1967 A
3375824 Krakauer Apr 1968 A
3395210 Lenahan et al. Jul 1968 A
3423290 Chappelle Jan 1969 A
3453180 Fraser, Jr. et al. Jul 1969 A
3466249 Anderson Sep 1969 A
3468471 Linder Sep 1969 A
3490437 Bakondy et al. Jan 1970 A
3519572 Kita Jul 1970 A
3533934 Armanini Oct 1970 A
3537189 Thompson Nov 1970 A
3548051 Hamilton Dec 1970 A
3556760 Bender et al. Jan 1971 A
3565987 Schuurs Feb 1971 A
3571940 Bender Mar 1971 A
3573063 Williams Mar 1971 A
3574950 Dantoni Apr 1971 A
3607858 Querry Sep 1971 A
3627878 Linsner Dec 1971 A
3629142 Marbach Dec 1971 A
3674860 Welter et al. Jul 1972 A
3714345 Hirata Jan 1973 A
3717708 Wada et al. Feb 1973 A
3730843 McKie, Jr. May 1973 A
3799740 Mincey Mar 1974 A
3803299 Nouel Apr 1974 A
3831293 Ingram et al. Aug 1974 A
3859047 Klein Jan 1975 A
3922145 Turner et al. Nov 1975 A
3932943 Briggs et al. Jan 1976 A
3944665 Galoian et al. Mar 1976 A
3945523 Wertlake Mar 1976 A
3964865 Das Jun 1976 A
3973002 Hagan et al. Aug 1976 A
3987159 Spona et al. Oct 1976 A
3993585 Pinto et al. Nov 1976 A
4001944 Williams Jan 1977 A
4002739 Turner et al. Jan 1977 A
4035924 Faure Jul 1977 A
4045176 Proksch et al. Aug 1977 A
4049673 Scheinberg Sep 1977 A
4056484 Heimburger Nov 1977 A
4059491 Iwasa et al. Nov 1977 A
4080265 Antonik Mar 1978 A
4089944 Thomas May 1978 A
4109396 Fraser Aug 1978 A
4127502 Mutti et al. Nov 1978 A
4134943 Knitsch Jan 1979 A
4141856 Dorwart, Jr. et al. Feb 1979 A
4141887 Seufert Feb 1979 A
4155186 Robinson May 1979 A
4157383 Sedlacek et al. Jun 1979 A
4188318 Shanbrom Feb 1980 A
4189400 Proksch et al. Feb 1980 A
4202665 Wenz et al. May 1980 A
4218321 Sasaki Aug 1980 A
4249826 Studievic et al. Feb 1981 A
4284725 Fennel, III et al. Aug 1981 A
4287087 Brinkhous et al. Sep 1981 A
4298441 Seidel et al. Nov 1981 A
4323478 Adams et al. Apr 1982 A
4324685 Louderback Apr 1982 A
4330463 Luijerink May 1982 A
4333767 Nass Jun 1982 A
4337240 Saklad Jun 1982 A
4442655 Stroetmann Apr 1984 A
4456590 Rubinstein Jun 1984 A
4465774 Huang et al. Aug 1984 A
4495278 Thomas Jan 1985 A
4506455 Rossi Mar 1985 A
4543335 Sommer et al. Sep 1985 A
4581231 Purcell et al. Apr 1986 A
4595021 Shimizu et al. Jun 1986 A
4614795 Chavin et al. Sep 1986 A
4624927 Fukushima et al. Nov 1986 A
4650678 Fuhge Mar 1987 A
4664913 Mielke May 1987 A
4666725 Yamashita et al. May 1987 A
4687664 Philapitsch et al. Aug 1987 A
4716119 Rehner et al. Dec 1987 A
4722790 Cawley et al. Feb 1988 A
4730460 Coelho Mar 1988 A
4731330 Hill et al. Mar 1988 A
4746730 De Ambrosi et al. May 1988 A
4780314 Graves Oct 1988 A
4806343 Carpenter et al. Feb 1989 A
4812557 Yasushi et al. Mar 1989 A
4813210 Masuda Mar 1989 A
4850353 Stasz et al. Jul 1989 A
4874690 Goodrich, Jr Oct 1989 A
4877608 Lee et al. Oct 1989 A
4877741 Babcock et al. Oct 1989 A
4902287 Carmen Feb 1990 A
4904641 Eibl Feb 1990 A
4973327 Goodrich, Jr Nov 1990 A
4986998 Yoo et al. Jan 1991 A
4994057 Carmen Feb 1991 A
5043261 Goodrich Aug 1991 A
5045446 Goodrich, Jr Sep 1991 A
5059036 Richison Oct 1991 A
5059518 Kortright et al. Oct 1991 A
5061789 Moller et al. Oct 1991 A
5063178 Toomey Nov 1991 A
5073378 Shoshan et al. Dec 1991 A
5114004 Isono May 1992 A
5118795 Rubinstein Jun 1992 A
5129162 Hemmersbach et al. Jul 1992 A
5147803 Enomoto Sep 1992 A
5151500 Wismer-Pedersen et al. Sep 1992 A
5171661 Goodrich, Jr Dec 1992 A
5178884 Goodrich Jan 1993 A
5213814 Goodrich, Jr May 1993 A
5242792 Rudolph et al. Sep 1993 A
5257983 Garyantes Nov 1993 A
5260420 Burnouf-Radosevich et al. Nov 1993 A
5262325 Zimmermann et al. Nov 1993 A
5304383 Eibl et al. Apr 1994 A
5309649 Bergmann May 1994 A
5340592 Goodrich, Jr Aug 1994 A
5399670 Bhattacharya et al. Mar 1995 A
5411893 Eden et al. May 1995 A
5420250 Lontz May 1995 A
5425951 Goodrich, Jr. Jun 1995 A
5464471 Whalen et al. Nov 1995 A
5514123 Adolf May 1996 A
5514586 Hottinger et al. May 1996 A
5527260 Kameyama Jun 1996 A
5547873 Magneson et al. Aug 1996 A
5551781 Wilkes Sep 1996 A
5585007 Antanavich et al. Dec 1996 A
5637345 Lee et al. Jun 1997 A
5648206 Goodrich, Jr Jul 1997 A
5651966 Read et al. Jul 1997 A
5656498 Iijima Aug 1997 A
5690963 Spargo et al. Nov 1997 A
5695764 Bontemps Dec 1997 A
5698535 Geczy et al. Dec 1997 A
5736313 Spargo et al. Apr 1998 A
5747268 Herring et al. May 1998 A
5750330 Tometsko et al. May 1998 A
5750657 Edwardson et al. May 1998 A
5759774 Hackett Jun 1998 A
5795571 Cederholm-Wlliams et al. Aug 1998 A
5831027 McIntosh et al. Nov 1998 A
5834418 Brazeau et al. Nov 1998 A
5837519 Savage et al. Nov 1998 A
5849473 Cabrera Dec 1998 A
5853388 Semel Dec 1998 A
5860222 Leander Jan 1999 A
5861311 Maples et al. Jan 1999 A
5891393 Read et al. Apr 1999 A
5919766 Osterberg et al. Jul 1999 A
5919935 Platz et al. Jul 1999 A
5928213 Barney et al. Jul 1999 A
5946931 Lomax Sep 1999 A
5968831 Shukla et al. Oct 1999 A
5985582 Triscott Nov 1999 A
6007529 Gustafsson Dec 1999 A
6034060 Yamamoto et al. Mar 2000 A
6060233 Wiggins May 2000 A
6132454 Fellows Oct 2000 A
6139878 Summaria et al. Oct 2000 A
6148536 Iijima Nov 2000 A
6187553 Antignani et al. Feb 2001 B1
6199297 Wisniewski Mar 2001 B1
6218195 Gottschalk et al. Apr 2001 B1
6221575 Roser Apr 2001 B1
6270985 Gottschalk et al. Aug 2001 B1
6323036 Chapoteau et al. Nov 2001 B1
6323037 Lauto et al. Nov 2001 B1
6331557 Brugnara et al. Dec 2001 B1
6346216 Kent Feb 2002 B1
6350584 Gottschalk et al. Feb 2002 B1
6358236 DeFoggi et al. Mar 2002 B1
6358678 Bakaltcheva et al. Mar 2002 B1
6372423 Braun Apr 2002 B1
6381870 Kohlman May 2002 B1
6398771 Gustafsson Jun 2002 B1
6416717 Suzuki et al. Jul 2002 B1
6472162 Coelho et al. Oct 2002 B1
6517526 Tamari Feb 2003 B1
6566504 Bhattacharya et al. May 2003 B2
6608237 Li Aug 2003 B1
RE38431 Miekka et al. Feb 2004 E
6773425 Tamari Aug 2004 B1
6852540 Makiuchi et al. Feb 2005 B2
6869901 Lubker, II Mar 2005 B2
6872576 McIntyre Mar 2005 B1
6887852 Paik et al. May 2005 B1
6890512 Roser et al. May 2005 B2
6981337 Jones Jan 2006 B2
7041635 Kim et al. May 2006 B2
7048709 Goudaliez May 2006 B2
7112320 Beaulieu et al. Sep 2006 B1
7175614 Gollier Feb 2007 B2
7179951 Krishnaswamy-Mirle Feb 2007 B2
7202341 McGinnis Apr 2007 B2
7249880 Zambaux Jul 2007 B2
7343696 Covert Mar 2008 B2
7358039 Fischer et al. Apr 2008 B2
7363726 Wang Apr 2008 B2
7411038 Haynie Aug 2008 B2
7422726 Hammerstedt Sep 2008 B2
7435795 McGinnis Oct 2008 B2
7473246 Vancaillie Jan 2009 B2
7480032 Braig et al. Jan 2009 B2
7482020 Hennessy et al. Jan 2009 B2
7501493 Roser Mar 2009 B2
7569184 Wandell et al. Aug 2009 B2
7618406 Roger Nov 2009 B2
7678888 Friedman et al. Mar 2010 B2
7727743 Bardat et al. Jun 2010 B2
7776022 McCarthy Aug 2010 B2
7811558 Ho et al. Oct 2010 B2
7879332 Zurlo et al. Feb 2011 B2
7931919 Bakaltcheva Apr 2011 B2
7966746 Py Jun 2011 B2
8013022 DeAngelo Sep 2011 B2
8053248 Bakaltcheva Nov 2011 B2
8057872 Chen Nov 2011 B2
8097403 Ho Jan 2012 B2
8187475 Hecker et al. May 2012 B2
8235965 Roger Aug 2012 B2
8236355 Eijkenboom Aug 2012 B2
8268362 Braun et al. Sep 2012 B2
8277837 Fischer et al. Oct 2012 B2
8313654 Piazza et al. Nov 2012 B2
8372343 Goldstein Feb 2013 B2
8377882 Schneider Feb 2013 B2
8407912 Hubbard, Jr. et al. Apr 2013 B2
8430970 Swami et al. Apr 2013 B2
8449520 Pepper May 2013 B2
8450079 Kovalenko et al. May 2013 B2
8491178 Breidenthal Jul 2013 B2
8492081 Nichols Jul 2013 B2
8512754 Needham Aug 2013 B2
8516714 Biemans Aug 2013 B2
8518452 Bjornstrup Aug 2013 B2
8529961 Campbell et al. Sep 2013 B2
8598319 Michel et al. Dec 2013 B2
8603063 Grimm Dec 2013 B2
8858681 Harp Oct 2014 B2
8951565 McCarthy Feb 2015 B2
9011846 Overholser et al. Apr 2015 B2
9046303 Yagi Jun 2015 B2
9132206 McCarthy Sep 2015 B2
9161527 Cutting Oct 2015 B2
9469835 Bronshtein Oct 2016 B2
9545379 Liu Jan 2017 B2
9561184 Khan Feb 2017 B2
9561893 Root Feb 2017 B2
9696284 Rannisto et al. Jul 2017 B2
9796273 Ragazzini Oct 2017 B2
9863699 Corbin, III Jan 2018 B2
9863701 Robinson Jan 2018 B2
10058091 Wolf Aug 2018 B2
10377520 Root Aug 2019 B2
10492507 Rizvi Dec 2019 B2
10507165 Di Naro Dec 2019 B2
10539367 Corbin, III Jan 2020 B2
10723497 Diaz Guerrero Jul 2020 B2
10793327 Weimer Oct 2020 B2
10830535 Oprins et al. Nov 2020 B2
10844366 Durance et al. Nov 2020 B2
11236942 Christ Feb 2022 B2
11236943 Christ Feb 2022 B2
20010004641 Hawkins Jun 2001 A1
20010031721 Webb et al. Oct 2001 A1
20020035354 Mirle Mar 2002 A1
20020146409 Herring et al. Oct 2002 A1
20030065149 McGinnis Apr 2003 A1
20030068416 Burgess et al. Apr 2003 A1
20030080056 Boos et al. May 2003 A1
20030104508 Gempeler et al. Jun 2003 A1
20030134418 Mitaka Jul 2003 A1
20030143566 Helftenbein Jul 2003 A1
20040005310 Rapp et al. Jan 2004 A1
20040081588 Hammerstedt Apr 2004 A1
20040126880 Manders et al. Jul 2004 A1
20040132207 Arima et al. Jul 2004 A1
20050158856 Edelson et al. Jul 2005 A1
20050170068 Roodink et al. Aug 2005 A1
20050282734 Kadima et al. Dec 2005 A1
20060004189 Gandy Jan 2006 A1
20060134084 Wolkers et al. Jun 2006 A1
20060182652 Burgess et al. Aug 2006 A1
20060216687 Alves-Filho Sep 2006 A1
20060263759 Alves-Filho Nov 2006 A1
20070014780 Woolverton Jan 2007 A1
20070110817 Shestakov May 2007 A1
20070116599 Walters et al. May 2007 A1
20070135343 Webb et al. Jun 2007 A1
20070166389 Bakaltcheva Jul 2007 A1
20070275028 Barry et al. Nov 2007 A1
20080038818 Natan et al. Feb 2008 A1
20080063697 Bedard Mar 2008 A1
20080256822 Suzuki Apr 2008 A1
20080119818 Bakaltcheva May 2008 A1
20080145444 Merchant et al. Jun 2008 A1
20080193386 Yoo et al. Aug 2008 A1
20080206293 Toreki Aug 2008 A1
20080234653 McCarthy Sep 2008 A1
20080234654 McCarthy Sep 2008 A1
20080249499 Vancaillie Oct 2008 A1
20080299212 Kim et al. Dec 2008 A1
20090036862 Grimm Feb 2009 A1
20090107001 McCarthy Apr 2009 A1
20090113753 Pepper May 2009 A1
20090223080 McCarthy Sep 2009 A1
20090324929 Yamakawa Dec 2009 A1
20100049156 Dickhorner Feb 2010 A1
20100144595 Bucci Jun 2010 A1
20100159023 Bjornstrup Jun 2010 A1
20100168018 Pikal et al. Jul 2010 A1
20110008458 Gandy et al. Jan 2011 A1
20110008459 Marguerre et al. Jan 2011 A1
20110020299 Bader Jan 2011 A1
20110114524 Eibl May 2011 A1
20110142948 Langer et al. Jun 2011 A1
20110144613 Pepper Jun 2011 A1
20110177541 Martinoli et al. Jul 2011 A1
20110183311 Ho Jul 2011 A1
20110263408 Suto et al. Oct 2011 A1
20110282325 Gregory Nov 2011 A1
20120027867 Fischer et al. Feb 2012 A1
20120040384 Stangier Feb 2012 A1
20120045518 Nielsen et al. Feb 2012 A1
20120070855 Mirshahi et al. Mar 2012 A1
20120141595 Tseng et al. Jun 2012 A1
20120156306 Weissman et al. Jun 2012 A1
20120231485 Onundarson Sep 2012 A1
20120252044 Rechner et al. Oct 2012 A1
20120329082 Viola et al. Dec 2012 A1
20130008048 Patel et al. Jan 2013 A1
20130019572 Beator et al. Jan 2013 A1
20130030161 Anitua Aldecoa Jan 2013 A1
20130040890 Guo et al. Feb 2013 A1
20130090291 Gulle et al. Apr 2013 A1
20130116410 Ivarsson et al. May 2013 A1
20130122107 Bakaltcheva May 2013 A1
20130126370 DiLiberto et al. May 2013 A1
20130143198 Sailliol Jun 2013 A1
20130149727 Aygen Jun 2013 A1
20130183661 Prante et al. Jul 2013 A1
20130195897 Teschner et al. Aug 2013 A1
20130195959 Patel Aug 2013 A1
20130202585 Bardat et al. Aug 2013 A1
20130243877 Haley et al. Sep 2013 A1
20130251695 Farmer et al. Sep 2013 A1
20130303842 Zeitels et al. Nov 2013 A1
20130316011 Ahn et al. Nov 2013 A1
20130326899 Yagi Dec 2013 A1
20140178513 Matthews Jun 2014 A1
20140212895 Lim Jul 2014 A1
20140259724 McCarthy Sep 2014 A1
20140287643 Nozaki Sep 2014 A1
20140360891 Kline Dec 2014 A1
20150158652 Root Jun 2015 A1
20150354894 Corbin, III Dec 2015 A1
20160084572 Khan Mar 2016 A1
20160375184 Albert Dec 2016 A1
20170100339 Liu Apr 2017 A1
20170113824 Root Apr 2017 A1
20170203871 Murto Jul 2017 A1
20170258877 Bare et al. Sep 2017 A1
20170259186 Khan Sep 2017 A1
20170367322 Liu et al. Dec 2017 A1
20180128544 Corbin, III May 2018 A1
20180221418 Daniel Aug 2018 A1
20190000979 Cleek et al. Jan 2019 A1
20190030169 Ivarsson et al. Jan 2019 A1
20190106254 Weimer Apr 2019 A1
20190142694 Di Naro May 2019 A1
20200253826 Qiu Aug 2020 A1
20200288703 Parakin Sep 2020 A1
20200289728 Johnson et al. Sep 2020 A1
20200292231 Johnson et al. Sep 2020 A1
20210016943 Weimer Jan 2021 A1
20210127663 Paukkonen May 2021 A1
Foreign Referenced Citations (430)
Number Date Country
517248 Jul 1981 AU
590193 Nov 1989 AU
622133 Apr 1992 AU
8165698 Jan 2000 AU
744025 Feb 2002 AU
2002326819 Apr 2003 AU
2007205748 Nov 2009 AU
2012205238 Aug 2012 AU
64922 Sep 2006 BG
745958 Nov 1966 CA
780792 Mar 1968 CA
787838 Jun 1968 CA
835939 Mar 1970 CA
843883 Jun 1970 CA
1260389 Sep 1989 CA
1210267 Mar 1999 CN
1242429 Jan 2000 CN
1376520 Oct 2002 CN
1410537 Apr 2003 CN
1156282 Jul 2004 CN
1157194 Jul 2004 CN
1162160 Aug 2004 CN
1187616 Feb 2005 CN
1220512 Sep 2005 CN
1745627 Mar 2006 CN
1250718 Apr 2006 CN
1267340 Aug 2006 CN
1270731 Aug 2006 CN
1281161 Oct 2006 CN
1931025 Mar 2007 CN
101152211 Apr 2008 CN
101216432 Jul 2008 CN
101299029 Nov 2008 CN
101310728 Nov 2008 CN
100469359 Mar 2009 CN
101416985 Apr 2009 CN
100531723 Aug 2009 CN
101579356 Nov 2009 CN
100584942 Jan 2010 CN
101618120 Jan 2010 CN
101167745 Jun 2010 CN
101766252 Jul 2010 CN
101833009 Sep 2010 CN
101879333 Nov 2010 CN
101893628 Nov 2010 CN
101893639 Nov 2010 CN
101957364 Jan 2011 CN
101971972 Feb 2011 CN
101347617 Apr 2011 CN
102000022 Apr 2011 CN
102008504 Apr 2011 CN
102012433 Apr 2011 CN
102050876 May 2011 CN
102078306 Jun 2011 CN
102106872 Jun 2011 CN
101433553 Aug 2011 CN
102207504 Oct 2011 CN
101385855 Nov 2011 CN
102229670 Nov 2011 CN
102241767 Nov 2011 CN
102250238 Nov 2011 CN
101461939 Jan 2012 CN
102337252 Feb 2012 CN
102363634 Feb 2012 CN
102426240 Apr 2012 CN
102426258 Apr 2012 CN
101285086 May 2012 CN
102435743 May 2012 CN
101830979 Jun 2012 CN
101843335 Jun 2012 CN
102507934 Jun 2012 CN
102512418 Jun 2012 CN
102524812 Jul 2012 CN
102552154 Jul 2012 CN
102579737 Jul 2012 CN
102590496 Jul 2012 CN
102590529 Jul 2012 CN
102600074 Jul 2012 CN
102600231 Jul 2012 CN
102600508 Jul 2012 CN
101899110 Aug 2012 CN
102614219 Aug 2012 CN
102628869 Aug 2012 CN
102645358 Aug 2012 CN
101816789 Sep 2012 CN
102688200 Sep 2012 CN
102692514 Sep 2012 CN
101900712 Oct 2012 CN
102327289 Oct 2012 CN
102697581 Oct 2012 CN
102746396 Oct 2012 CN
102754848 Oct 2012 CN
102327288 Nov 2012 CN
102793053 Nov 2012 CN
101843289 Dec 2012 CN
102854322 Jan 2013 CN
102866220 Jan 2013 CN
102866255 Jan 2013 CN
102879560 Jan 2013 CN
101948630 Feb 2013 CN
102908321 Feb 2013 CN
102908368 Feb 2013 CN
102093385 Mar 2013 CN
102228683 Mar 2013 CN
102240310 Mar 2013 CN
102988974 Mar 2013 CN
102210854 Apr 2013 CN
103007280 Apr 2013 CN
103039693 Apr 2013 CN
103054816 Apr 2013 CN
101756013 May 2013 CN
103076455 May 2013 CN
103113456 May 2013 CN
102258780 Jun 2013 CN
102319425 Jun 2013 CN
102525954 Jun 2013 CN
102274493 Aug 2013 CN
203572189 Apr 2014 CN
106461327 Feb 2017 CN
277138 Nov 1992 CS
109659 Nov 1974 DE
2430447 Jan 1975 DE
112775 May 1975 DE
2617742 Jun 1977 DE
2617742 Jun 1977 DE
2365629 Jun 1983 DE
19729778 Jan 1999 DE
19729778 Jan 1999 DE
69521470 May 2002 DE
69133198 Jul 2003 DE
69810755 Aug 2003 DE
105923 Apr 1984 EP
121868 Oct 1984 EP
0157579 Oct 1985 EP
111777 Mar 1987 EP
0124018 Nov 1987 EP
204045 Jan 1988 EP
0284249 Sep 1988 EP
0284249 Sep 1988 EP
0335682 Oct 1989 EP
0335682 Oct 1989 EP
0343596 Nov 1989 EP
0343596 Nov 1989 EP
0343596 Nov 1989 EP
206448 Nov 1990 EP
215050 Feb 1991 EP
445108 Sep 1991 EP
392377 Feb 1995 EP
593176 Mar 1995 EP
2729932 Aug 1996 EP
2729932 Aug 1996 EP
752097 Jan 1997 EP
485377 May 1999 EP
1021726 Jul 2000 EP
1171163 Jan 2002 EP
1243275 Sep 2002 EP
1286706 Mar 2003 EP
876155 Jul 2004 EP
1087990 Sep 2004 EP
1087990 Sep 2004 EP
1113269 Oct 2006 EP
1870649 Dec 2007 EP
997735 Jan 2008 EP
1958618 Aug 2008 EP
1958618 Aug 2008 EP
1730299 Jun 2011 EP
2371343 Dec 2011 EP
2431024 Mar 2012 EP
2431024 Mar 2012 EP
2564481 Mar 2013 EP
2574350 Apr 2013 EP
1407780 May 2013 EP
1407780 May 2013 EP
3290064 Mar 2018 EP
2001727 Oct 1969 FR
2160285 Jun 1973 FR
2187909 Jan 1974 FR
2224118 Oct 1974 FR
2227276 Nov 1974 FR
2363577 Mar 1978 FR
2475737 Aug 1981 FR
2600998 Jan 1988 FR
2717782 Sep 1995 FR
2729932 Aug 1996 FR
2814239 Mar 2002 FR
2963556 Feb 2012 FR
353286 Jul 1931 GB
425567 Mar 1935 GB
450146 Jul 1936 GB
450146 Jul 1936 GB
491515 Sep 1938 GB
620573 Mar 1949 GB
727148 Mar 1955 GB
731104 Jun 1955 GB
748784 May 1956 GB
748784 May 1956 GB
770075 Mar 1957 GB
807781 Jan 1959 GB
814491 Jun 1959 GB
814491 Jun 1959 GB
853288 Nov 1960 GB
859609 Jan 1961 GB
906860 Sep 1962 GB
911181 Nov 1962 GB
917012 Jan 1963 GB
941019 Nov 1963 GB
979759 Jan 1965 GB
1003748 Sep 1965 GB
1073172 Jun 1967 GB
1074461 Jul 1967 GB
1186544 Apr 1970 GB
1206033 Sep 1970 GB
1206033 Sep 1970 GB
1222810 Feb 1971 GB
1266274 Mar 1972 GB
1337178 Nov 1973 GB
1372812 Nov 1974 GB
1391746 Apr 1975 GB
1480092 Jul 1977 GB
1486787 Sep 1977 GB
1486787 Sep 1977 GB
1497517 Jan 1978 GB
1507435 Apr 1978 GB
1524712 Sep 1978 GB
1530748 Nov 1978 GB
1536725 Dec 1978 GB
1551792 Aug 1979 GB
1551928 Sep 1979 GB
1563839 Apr 1980 GB
2148090 Jul 1987 GB
2167856 Dec 1988 GB
2564481 Jan 2019 GB
1064142 Feb 1985 IT
S52156921 Dec 1977 JP
S53091117 Aug 1978 JP
S5426961 Feb 1979 JP
S5571452 May 1980 JP
S56127307 Oct 1981 JP
S56127308 Oct 1981 JP
S56160991 Dec 1981 JP
S5772911 May 1982 JP
S57122796 Jul 1982 JP
S57142561 Sep 1982 JP
S57159561 Oct 1982 JP
S58131566 Aug 1983 JP
S59088042 May 1984 JP
S59136657 Aug 1984 JP
S59181224 Oct 1984 JP
S59212768 Dec 1984 JP
S59218960 Dec 1984 JP
S60168051 Aug 1985 JP
S61040752 Feb 1986 JP
S61053567 Mar 1986 JP
S61128974 Jun 1986 JP
S61155332 Jul 1986 JP
S61225652 Oct 1986 JP
S61282054 Dec 1986 JP
S62010019 Jan 1987 JP
S62138433 Jun 1987 JP
H63-036828 Feb 1988 JP
H63-036828 Feb 1988 JP
S63157936 Jun 1988 JP
1021741 Apr 1989 JP
H1247060 Oct 1989 JP
H2221859 Sep 1990 JP
H07270405 Oct 1995 JP
H09020687 Jan 1997 JP
H09222427 Aug 1997 JP
2657092 Sep 1997 JP
H1045616 Feb 1998 JP
H10108907 Apr 1998 JP
H10-165480 Jun 1998 JP
3140797 Mar 2001 JP
3142192 Mar 2001 JP
3219181 Oct 2001 JP
2002029977 Jan 2002 JP
2002052067 Feb 2002 JP
3292760 Jun 2002 JP
3365091 Jan 2003 JP
2003055256 Feb 2003 JP
2003055257 Feb 2003 JP
2003-144523 May 2003 JP
2003339346 Dec 2003 JP
2004049493 Feb 2004 JP
3543144 Jul 2004 JP
3712989 Nov 2005 JP
2006036749 Feb 2006 JP
2007197353 Aug 2007 JP
4024506 Dec 2007 JP
4059299 Mar 2008 JP
2006545011 May 2008 JP
2008527741 Jul 2008 JP
2009297212 Dec 2009 JP
2010266086 Nov 2010 JP
2011239 Jan 2011 JP
2011120763 Jun 2011 JP
2012051895 Mar 2012 JP
5002106 Aug 2012 JP
5037621 Oct 2012 JP
5049447 Oct 2012 JP
5087815 Dec 2012 JP
5252909 Jul 2013 JP
5340945 Nov 2013 JP
2014028661 Feb 2014 JP
2014028661 Feb 2014 JP
5960660 Aug 2016 JP
2017-517335 Jun 2017 JP
6219922 Oct 2017 JP
6305870 Apr 2018 JP
100197297 Jun 1999 KR
20000020804 Apr 2000 KR
100503629 Jul 2005 KR
20060005770 Jan 2006 KR
100631188 Oct 2006 KR
100767541 Oct 2007 KR
100857273 Sep 2008 KR
100908742 Jul 2009 KR
20110008382 Jan 2011 KR
101157096 Jun 2012 KR
101200423 Nov 2012 KR
20130009161 Jan 2013 KR
20130034991 Apr 2013 KR
20130053609 May 2013 KR
2011202 Apr 1994 RU
2028130 Feb 1995 RU
2028133 Feb 1995 RU
2080865 Jun 1997 RU
2090165 Sep 1997 RU
2090166 Sep 1997 RU
2121364 Nov 1998 RU
2193868 Dec 2002 RU
2197267 Jan 2003 RU
2242759 Dec 2004 RU
2266542 Dec 2005 RU
2273026 Mar 2006 RU
2314527 Jan 2008 RU
2322243 Apr 2008 RU
2332666 Aug 2008 RU
2325655 Nov 2008 RU
2357252 May 2009 RU
2426548 Aug 2011 RU
2442984 Feb 2012 RU
2455014 Jul 2012 RU
2456602 Jul 2012 RU
2463063 Oct 2012 RU
2012137892 Feb 2013 RU
2478958 Apr 2013 RU
2492867 Sep 2013 RU
548275 Feb 1977 SU
654238 Mar 1979 SU
686732 Sep 1979 SU
700129 Nov 1979 SU
786954 Dec 1980 SU
1344354 Oct 1987 SU
1592717 Sep 1990 SU
1678371 Sep 1991 SU
1716443 Feb 1992 SU
1752187 Jul 1992 SU
200600103 Jan 2006 TW
I358264 Feb 2012 TW
26543 Sep 2007 UA
WO-1992013495 Aug 1992 WO
WO-1992014360 Sep 1992 WO
WO-1995012127 May 1995 WO
WO-1995015763 Jun 1995 WO
9527180 Oct 1995 WO
WO-9527180 Oct 1995 WO
9629556 Sep 1996 WO
WO-9629556 Sep 1996 WO
9631748 Oct 1996 WO
WO-9631748 Oct 1996 WO
WO-1997046883 Dec 1997 WO
0036353 Jun 2000 WO
WO-0036353 Jun 2000 WO
WO-2000-036353 Jun 2000 WO
WO-2000047187 Aug 2000 WO
WO-2001064228 Sep 2001 WO
WO-2002083157 Oct 2002 WO
WO-2002083737 Oct 2002 WO
WO-2002087540 Nov 2002 WO
WO-2003082310 Oct 2003 WO
WO 2005089816 Sep 2005 WO
2006000422 Jan 2006 WO
WO-2006000422 Jan 2006 WO
2006028648 Mar 2006 WO
WO-2006028648 Mar 2006 WO
WO-2006054519 May 2006 WO
2006028648 Jan 2007 WO
WO-2006028648 Jan 2007 WO
2007104760 Sep 2007 WO
WO-2007104760 Sep 2007 WO
WO-2007104760 Apr 2008 WO
2008115548 Sep 2008 WO
WO-2008108549 Sep 2008 WO
WO-2008115548 Sep 2008 WO
2008130602 Oct 2008 WO
WO-2008-130602 Oct 2008 WO
WO-2008130602 Oct 2008 WO
2010019217 Feb 2010 WO
WO-2010019217 Feb 2010 WO
2010033169 Mar 2010 WO
WO-2010033169 Mar 2010 WO
2010093429 Aug 2010 WO
WO-2010093429 Aug 2010 WO
WO-2012092712 Jul 2012 WO
WO-2012098358 Jul 2012 WO
WO-2012101109 Aug 2012 WO
WO-2012140209 Oct 2012 WO
WO-2012159075 Nov 2012 WO
WO-2013013537 Jan 2013 WO
WO-2013042868 Mar 2013 WO
WO-2013057219 Apr 2013 WO
2013062479 May 2013 WO
WO-2013-062479 May 2013 WO
WO-2013062479 May 2013 WO
WO-2013076507 May 2013 WO
WO-2013085502 Jun 2013 WO
2014033228 Mar 2014 WO
WO-2014033228 Mar 2014 WO
2014165222 Oct 2014 WO
WO-2014-165222 Oct 2014 WO
WO-2014165222 Oct 2014 WO
2015191599 Dec 2015 WO
WO-2015191599 Dec 2015 WO
2015191599 Apr 2016 WO
WO-2015191599 Apr 2016 WO
2019074886 Apr 2019 WO
WO-2019074886 Apr 2019 WO
WO 2020185909 Sep 2020 WO
WO-2020242552 Dec 2020 WO
Non-Patent Literature Citations (25)
Entry
US 8,359,766 B2, 01/2013, Hubbard, Jr. et al. (withdrawn)
US 8,359,766, 01/2013. (withdrawn).
Cherry, Christopher Lee Albert, “Development of Novel Containment Systems for Freeze-Drying,” a thesis submitted to Cardiff Metropolitan University, Apr. 10, 2013.
Glassberg et al., “Freeze-dried Plasma at the Point of Injury: from Concept to Doctrine”, SHOCK, Dec. 2013, vol. 40, No. 6, pp. 444-450.
Cherry, Chris, “Containment systems for freeze-drying,” ISL-FD, Sep. 7, 2015.
Cannon, Jeremy W. M.D., “Prehospital Damage-Control Resuscitation”, The New England Journal of Medicine, Jul. 26, 2018, pp. 387-388.
Sperry et al., “Prehospital Plasma during Air Medical Transport in Trauma Patients at Risk for Hemorrhagic Shock”, The New England Journal of Medicine, Jul. 26, 2018, pp. 315-326.
Soares, Jeffrey M., “Saving Lives with Freeze-dried Plasma”, The United States Army, Nov. 27, 2017, pp. 1-5. https://www.army.mil/article/197409.
Pan et al, “Study of Banana Dehydration Using Sequential Infrared Radiation Heating and Freeze-Drying”, LWT—Food Science and Technology, 2008 v. 41, pp. 1944-1951.
International Search Report and Written Opinion, PCT/US2018/054943, dated Jan. 25, 2019.
Official Action for Canada Patent. Application No. 3078625, dated Jul. 16, 2021, 3 pages.
Official Action (with English translation) for Japan Patent Application No. 2020-540696, dated Aug. 24, 2021, 17 pages.
Official Action for U.S. Appl. No. 16/154,976, dated Dec. 20, 2019, 12 pages.
Official Action for U.S. Appl. No. 16/154,976, dated Apr. 13, 2020, 9 pages.
Notice of Allowance for U.S. Appl. No. 16/154,976, dated Jun. 12, 2020, 9 pages.
International Search Report and Written Opinion for International (PCT) Patent Application No. PCT/US2020/022113, dated Nov. 5, 2020, 45 pages.
International Search Report and Written Opinion for International (PCT) Patent Application No. PCT/US2020/022120, dated Nov. 26, 2020, 17 pages.
Invitation to Pay Additional Fees for International (PCT) Patent Application No. PCT/US2020/022120, dated Oct. 1, 2020, 11 pages.
International Search Report and Written Opinion for International (PCT) Patent Application No. PCT/US2020/022128, dated Sep. 4, 2020, 12 pages.
Official Action (with English abstract) for China Patent Application No. 201880064085.6, dated Jul. 15, 2021, 12 pages.
Official Action for U.S. Appl. No. 16/815,843, dated Jun. 16, 2021, 11 pages.
Notice of Allowance for U.S. Appl. No. 16/815,843, dated Sep. 24, 2021, 5 pages.
Official Action (with English abstract) for Chinese Patent Application No. 201880064085.6, dated Mar. 11, 2022, 9 pages.
Official Action (with English translation) for Japan Patent Application No. 2020-540696, dated Jan. 11, 2022, 16 pages.
Official Action for U.S. Appl. No. 16/815,904, dated Feb. 7, 2022, 13 pages.
Related Publications (1)
Number Date Country
20210016943 A1 Jan 2021 US
Provisional Applications (2)
Number Date Country
62569858 Oct 2017 US
62571087 Oct 2017 US
Continuations (1)
Number Date Country
Parent 16154976 Oct 2018 US
Child 17010083 US